The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 256 participants.

Also called NCT06408532

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 256 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06408532
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06408532. Randomized; single masking; primary purpose treatment. Start 2024-04-30 (anticipated); primary completion 2024-10-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
IDegLira
Intervention (Drug)
Premixed insulin
Lead sponsor
Peking University People's Hospital (class: other)

Record details

Record id
cardio:ct-nct06408532
Content hash
56418c47d2ae3e49f05f1032320b01d210bef0465938d262615d8523d6bfc3a2